Next Generation Sequencing (NGS) Market Size, Share, Growth, and Industry Analysis, By Type ( Targeted Sequencing,Whole Exome Sequencing,Whole Genome Sequencing ), By Application ( Academic & Government Research Institutes,Pharmaceutical Companies,Biotechnology Companies,Hospitals & Clinics ), Regional Insights and Forecast to 2035

Next Generation Sequencing (NGS) Market Overview

Global Next Generation Sequencing (NGS) market size is estimated at USD 4079.54 million in 2026, set to expand to USD 5539.02 million by 2035, growing at a CAGR of 3.4%.

The Next Generation Sequencing (NGS) Market Report shows that Targeted sequencing accounts for about 57.6 % share of sequencing types, making it the largest segment within the global NGS industry in 2024. Additionally, consumables (sequencing kits and reagents) represent 48.6 % share of NGS products due to recurrent use across sequencing workflows. The sequencing workflow holds an estimated 64.5 % share of total NGS value due to high demand for sample preparation, library construction, and high‑throughput sequencing runs. These statistics emphasize the dominance of targeted resequencing and consumable‑driven segmentation in the Next Generation Sequencing (NGS) Market Size.

In the Next Generation Sequencing (NGS) Market in the USA, North America holds approximately 55.65 % share of global NGS market presence as of 2024, with the United States leading NGS adoption due to robust research funding, extensive genomic initiatives, and institutional usage across clinical and research settings. The U.S. also contributes significantly to sequence service collaboration deployments, including multi‑center genome surveillance programs and partnerships to support infectious disease genotype workflows. The U.S. market’s numeric footprint, measured by sequencing runs, platform installations, and consumption volumes for reagents, underscores its leadership in Next Generation Sequencing (NGS) Market Insights globally.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: Targeted sequencing technologies account for 57.6 % share of total sequencing type installations in 2024.
• Major Market Restraint: Consumables segment dominance reflects 48.6 % share, creating pricing sensitivity and supply challenges.
• Emerging Trends: Sequencing workflow demand occupies 64.5 % share of total NGS pipeline usage due to intensive sample processing requirements.
• Regional Leadership: North America holds 55.65 % share of global Next Generation Sequencing deployment and utilization.
• Competitive Landscape: Top sequencing platforms represent >60 % share of installed NGS instruments across clinical research and genomic centers.
• Market Segmentation: Whole genome, whole exome and targeted sequencing represent major segments with targeted sequencing leading at 57.6 % share.
• Recent Development: Consumables held 48.6 % share of NGS product deployment in sequencing workflows in 2024.

Next Generation Sequencing (NGS) Market Latest Trends

The Next Generation Sequencing (NGS) Market Trends spotlight real‑world numeric measures demonstrating technology adoption. In 2024, Targeted sequencing comprised an estimated 57.6 % share of total sequencing types used across research and clinical laboratories globally, highlighting preference for focused genomic analysis over broad scale methods. The sequencing workflow segment, including sample preparation, library construction, and instrument runs, carried an approximate 64.5 % share of NGS pipeline activities, showing dense demand for end‑to‑end sequencing processes. Consumables, including reagents and kits for DNA library preparation and sequencing reactions, accounted for around 48.6 % share of product usage within the global NGS ecosystem, reflecting repeat purchase frequency in high‑throughput settings.

Targeted and whole exome sequencing technologies show accelerated integration in oncology, infectious disease diagnostics, and pharmacogenomics workflows measured by volume of sequencing runs per month in clinical facilities. Connected with this, nanopore and long‑read sequencing platforms reported double‑digit increases in installed capacity across research networks, aligning with multi‑regional genomic surveillance programs. These numeric indicators support industry analysis for Next Generation Sequencing (NGS) Market Outlook in clinical and academic environments.

Next Generation Sequencing (NGS) Market Dynamics

DRIVER

"Rising Demand for Precision Genomic Sequencing Technologies."

The DRIVER for market growth remains the increasing requirement for precision genomic data across healthcare and research. Quantitatively, targeted sequencing technologies like amplicon panels and exon‑focused methods hold ~57.6 % share of sequencing workflows in 2024, demonstrating strong preference for high‑resolution, cost‑effective analysis in disease research and therapy development. High‑throughput sequencing operations now report thousands of sequencing runs per month in major genomics centers, reflecting adoption momentum. Concurrently, whole genome and whole exome sequencing applications continue to record high utilization in large‑scale population studies, with installations increasing in academic institutions by over 25 % relative units since 2022, illustrating the depth of technology integration. These numeric indicators of platform penetration, combined with educational and training programs aimed at expanding genomic analysis skills, illustrate the quantitative basis for Next Generation Sequencing (NGS) Market Growth Drivers.

RESTRAINT

"Supply Chain Constraints and Consumable Cost Sensitivity."

The MAJOR RESTRAINT lies in operational supply chain and consumable pricing pressures. In 2024, consumables accounted for roughly 48.6 % share of product usage in the NGS workflow, placing heavy emphasis on availability and pricing consistency. Sequencing reagents, primers, enzymes, and disposable flow cells remain subject to global supply chain variances and raw material fluctuations that affect lab adoption rates. Schools of medicine and smaller hospitals report capacity bottlenecks when reagents drop below critical stock levels, often causing delays in sequencing runs measured in hundreds of samples per week. This numeric volatility also affects sequencing facilities in regions with limited logistical support. Such data point to a quantifiable restraint in Next Generation Sequencing (NGS) Market Dynamics due to consumable dependency and inventory challenges.

OPPORTUNITY

"Expansion of Clinical Sequencing Initiatives and Bioinformatics Integration."

There is a strong OPPORTUNITY for expansion as sequencing uptake grows in clinical contexts, especially oncology and infectious disease interventions that use targeted and exome sequencing. Clinical laboratories are increasing sequence throughput by hundreds of runs per quarter, with multi‑hospital networks reporting double‑digit percentage increases in workflows using NGS. Emphasis on bioinformatics integration is critical; facilities are expanding analysis pipelines capable of managing millions of base pairs per sample, driving installations of additional data processing infrastructure by two‑fold in research settings year‑on‑year. These numerical shifts illustrate potential scale of NGS applications in clinical diagnostics, positioning the market for continued penetration in precision medicine frameworks.

CHALLENGE

"Shortage of Skilled Workforce and Data Interpretation Bottlenecks."

A quantifiable CHALLENGE is the shortage of qualified genomic analysts and bioinformatics professionals capable of interpreting complex data. Laboratories report more than 40 % of sequencing runs requiring specialized interpretation resources due to raw data complexity, leading to backlogs. This workforce gap slows turnaround times on diagnostic sequencing by measurable durations—labs report an average lag of 5 days per sample due to interpretation constraints. Limited training programs and high demand for bioinformatics professionals contribute to these bottlenecks. These figures exemplify workforce and analytics challenges in the Next Generation Sequencing (NGS) Market Outlook.

Next Generation Sequencing (NGS) Market Segmentation

Download Free Sample to learn more about this report.

The Next Generation Sequencing (NGS) Market Segmentation Analysis highlights type and application segments across platforms and end users. By type, Targeted Sequencing holds approx. 57.6 % share within sequencing utilization, while Whole Exome Sequencing and Whole Genome Sequencing account for significant portions of long‑read and comprehensive genomic mapping workflows. Application segmentation shows academic & government research institutes, pharmaceutical companies, biotechnology companies, and hospitals & clinics as leading end user categories. Consumable usage and sequencing volume distribution indicate that clinical research facilities and biotech firms collectively manage tens of thousands of sequences annually, reflecting segmentation depth in the Next Generation Sequencing (NGS) Market Analysis.

BY TYPE

Targeted Sequencing: Targeted sequencing technologies remain the foremost type in the Next Generation Sequencing (NGS) Market Report, representing approximately 57.6 % share of total sequencing activities worldwide in 2024. This numeric dominance reflects the practicality of sequencing selected genomic regions across oncology, genetic disorder panels, and pathogen genotyping applications. In oncology research alone, hundreds of cancer‑associated genes are routinely sequenced, with targeted panels producing tens of millions of reads per sample in high‑depth configurations. Research laboratories report installations of more than 1,000 targeted sequencing panels for clinical projects in the first half of 2025, a fact that bolsters targeted technologies’ share. Compared to whole genome approaches, targeted sequencing demands lower data storage, enabling faster analysis workflows and reducing turnaround metrics by measurable days. With its significant share and high run volumes, Targeted Sequencing remains an essential component of the Next Generation Sequencing Market Trends across both academic and clinical sectors.

Whole Exome Sequencing: Whole Exome Sequencing (WES) plays a critical role in the Next Generation Sequencing (NGS) Industry Report through its representation in diagnostic and therapeutic research contexts. WES focuses on protein‑coding regions of the genome, which comprise approximately ~1 % of the human genome yet contribute to a large portion of disease‑related variants. In research settings, more than 30,000 exome sequence samples are processed annually in national genomic programs, reflecting heavy reliance on this type. Clinical genetics laboratories track increased throughput, with exome runs often exceeding 500 samples per quarter in flagship studies centered on rare genetic disorders. The numeric footprint of WES deployments illustrates its centrality in sequence‑based investigations, where large sample cohorts accumulate data sets of billions of base pairs annually. Its measurable presence in sequencing infrastructures underscores WES’s role in Next Generation Sequencing (NGS) Market Insights for gene cataloging and personalized medicine.

Whole Genome Sequencing: Whole Genome Sequencing (WGS) represents a cornerstone type within the Next Generation Sequencing (NGS) Market Analysis, enabling full mapping of the entire genomic content. WGS is integral to population genomics projects where tens of thousands of individuals are sequenced as part of national health initiatives. For example, large programs report sequencing more than 50,000 whole genomes annually across research centers. This type provides comprehensive variant detection and structural insights that exceed other sequencing types in breadth of data, making it essential for complex disease research and anthropology studies. Though less dominant in share compared to targeted sequencing, WGS installations have expanded in academic consortia by numerically significant levels, with institutions processing millions of gigabases of sequence data per cycle. Whole Genome Sequencing’s extensive data outputs and deployment footprint reflect its importance in Next Generation Sequencing (NGS) Industry Report for both research and emerging clinical applications.

BY APPLICATION

Academic & Government Research Institutes: Academic & Government Research Institutes are among the largest application segments in the Next Generation Sequencing (NGS) Market Research Report. These institutes collectively handle tens of thousands of sequencing runs annually, with large consortia reporting sequences numbering in the low six‑figure ranges per year. Multi‑institutional projects such as population genomics research initiatives often coordinate sequencing data across more than 100 research labs globally. Government genomics initiatives typically fund extensive sequencing efforts, with projects aiming to sequence tens of thousands of human genomes for variant mapping and public health surveillance. Together, these numbers illustrate the dominant application role played by academic and government research institutes in NGS workflows, supported by instrument installations and data analysis infrastructures spread across multiple continents.

Pharmaceutical Companies: In the Next Generation Sequencing (NGS) Market Research Report, pharmaceutical companies apply sequencing technologies extensively in drug discovery pipelines and clinical trial stratification. Major drug developers deploy NGS platforms to process genomic data from tens of thousands of patient samples in precision pharmacogenomics studies. These companies invest in high‑throughput sequencing systems capable of generating hundreds of millions of reads per run, facilitating biomarker discovery, target validation, and safety profiling. In oncology drug programs, pharmaceutical NGS initiatives frequently sequence >10,000 tumor samples annually to refine therapeutic targets and companion diagnostics. Expanding use of NGS in biologics programs also contributes to quantitative increases in sequencing runs, making pharmaceutical application a core contributor to the overall Next Generation Sequencing (NGS) Market Share of sequencing workflows.

Biotechnology Companies: Biotechnology companies represent an active application segment within the global Next Generation Sequencing (NGS) Market Analysis. These firms regularly implement sequencing platforms to support genomic‑based innovation, including engineering microbial strains, optimizing gene editing platforms, and characterizing expression profiles in synthetic biology projects. In biotech settings, sequencing throughput often exceeds 500 runs per month for research programs that evaluate genetic modifications and phenotype associations. Instrument installations in biotech firms account for substantial portions of sequencing hardware deployed in the industry, often representing multi‑unit setups dedicated to pipeline expansion. With numerous companies conducting sequence‑driven R&D, biotech applications contribute heavily to cumulative sequence volumes and data analytics demands, highlighting the role of the Next Generation Sequencing (NGS) Market Forecast in addressing innovation metrics across biotechnological domains.

Hospitals & Clinics: Hospitals & Clinics are increasingly deploying NGS for routine diagnostics in complex disease identification, especially in oncology and rare genetic disorders. Major hospitals report sequencing more than 1,000 patient samples per quarter, using NGS to guide therapy decisions and precision care pathways. In clinical diagnostics, rapid turnaround of targeted panels supports same‑week results, with many facilities expanding capacity to accommodate tens of thousands of clinical tests annually. Hospitals also integrate bioinformatics pipelines to manage sequence interpretation, often processing terabytes of data for variant calling and gene expression profiling across patient cohorts. This quantifiable clinical usage underscores the significance of hospitals and clinics as application drivers in the Next Generation Sequencing (NGS) Industry Report due to measurable impacts on clinical throughput and diagnostic innovation.

Next Generation Sequencing (NGS) Market Regional Outlook

Download Free Sample to learn more about this report.

NORTH AMERICA

North America leads globally with approximately 55.65 % market share due to high instrument penetration, substantial research funding, and advanced sequencing infrastructure. The United States alone accounts for more than 90 % of North America’s installed sequencing platforms, with over 3,000 high-throughput sequencers deployed across academic, clinical, and pharmaceutical facilities. Sequencing centers in the U.S. process over 1.2 million runs annually, with oncology and rare disease studies comprising nearly 45 % of total workflows. Canada contributes by sequencing more than 200,000 exomes annually, while hospitals and clinics conduct over 100,000 clinical NGS tests per year. Consumables such as library preparation kits and reagents make up approximately 48.6 % of product utilization in the region, reflecting high repeat usage. From 2022 to 2025, North America installed over 1,500 new sequencing units, supporting research and clinical applications. Bioinformatics infrastructure in the region manages millions of base pairs per sample, demonstrating advanced data-handling capabilities.

EUROPE

Europe accounts for more than 25 % of the global NGS market, with Germany, the United Kingdom, and France driving regional growth. Multi-center research consortia sequence approximately 250,000 genomes and exomes annually, focusing on cancer, rare diseases, and population genomics. Hospitals report over 1,200 clinical sequencing workflows per quarter, primarily in oncology and genetic diagnostics. Germany and the UK collectively account for over 50 % of Europe’s installed sequencing platforms, including both short-read and long-read technologies. European regulatory bodies have allocated nearly €4.8 million to integrate NGS into clinical pipelines. Long-read sequencing platforms now process over 10,000 full genomes annually, supporting structural genomics research. Collaborative networks include more than 50 laboratories participating in multi-institutional projects for transcriptomics and methylation studies. Population-scale genomics initiatives allow individual labs to sequence tens of thousands of exomes per year, reinforcing Europe’s competitive position in the global market.

ASIA‑PACIFIC

Asia-Pacific represents nearly 15 % of the global NGS market, led by China, India, Japan, and South Korea. China’s national genomics initiatives process more than 50,000 genomes annually, primarily for population variant mapping and disease surveillance. India operates hundreds of sequencing platforms, processing over 20,000 clinical and research samples per year. Japan and South Korea collectively sequence more than 15,000 whole exomes and genomes annually, largely for oncology and rare disease studies. Singapore and Australia operate regional sequencing hubs that process over 10,000 samples annually for infectious disease monitoring. Since 2022, the region has seen over 25 % growth in installed sequencing units, including nanopore and long-read platforms for structural genomics. Biotech firms account for more than 30 % of total sequencing runs, particularly in synthetic biology and pharmacogenomics applications. Regional bioinformatics infrastructure manages millions of base pairs per sample, supporting high-throughput and multi-institutional workflows.

MIDDLE EAST & AFRICA

The Middle East and Africa represent an emerging segment of the NGS market, contributing approximately 4 % of the global share. South Africa leads sequencing initiatives in Africa, performing over 5,000 genomes annually, mainly for infectious disease and tuberculosis research. The UAE and Saudi Arabia have established clinical sequencing labs that process more than 1,000 patient samples per quarter for oncology and reproductive health diagnostics. Regional governments have funded over ten national genomic surveillance programs to support pathogen genomics and public health monitoring. Multi-country collaborations facilitate cross-border sequence sharing for HIV and malaria research, processing over 2,000 sequences annually. Training programs have enhanced the number of skilled bioinformaticians, with over 2,000 participants attending NGS capacity-building workshops since 2023. Emerging sequencing hubs integrate long-read and nanopore platforms, analyzing tens of thousands of base pairs per sample for structural variant and environmental genomics research. Although smaller than other regions, Middle East and Africa show rapid adoption trends with measurable increases in lab infrastructure and sequencing throughput, supporting the early-stage growth of the "Next Generation Sequencing (NGS) Market".

List of Top Next Generation Sequencing (NGS) Companies

• Illumina
• Thermo Fisher Scientific
• Pacific Biosciences of California
• Beijing Genomics Institute
• Qiagen
• Roche
• Agilent Technologies
• Perkinelmer
• Genomatix
• PierianDx
• Eurofins Scientific
• Gatc Biotech
• Oxford Nanopore Technologies
• Bio-Rad Laboratories
• DNASTAR
• Biomatters
• Partek
• New England Biolabs
• Myriad Genetics
• Macrogen

Top 2 Companies with Highest Market Share

• Illumina: Holds leading market share in sequencing platforms, supported by widespread installations and consumable usage metrics, representing one of the two highest share holders in the global NGS industry.
• Thermo Fisher Scientific: One of the top two companies by share of global sequencing instrument deployments and consumables consumption, especially across healthcare and biotech sectors.

Investment Analysis and Opportunities

Investment trends in the Next Generation Sequencing (NGS) Market Research Report indicate that accumulated global sequence capacity has expanded numerically, with thousands of new sequencing units installed across research, clinical, and biotech facilities between 2022 and 2025. Major research centers report installation increases exceeding 1,500 sequencing platforms in this period, reflecting confidence in NGS technologies as strategic assets. Government genomics initiatives have allocated significant numeric commitments to sequencing workflows; European regulatory support programs contributed €4.8 million to clinical sequencing operations, promoting adoption in hospitals and diagnostic labs. Moreover, academic consortium investments in NGS allow scaling of sample throughput, with many projects sequencing tens of thousands of genomes to support disease association studies. Biotech venture capital has likewise backed startups focused on long‑read and nanopore sequencing, with installed units increasing by measurable double‑digit percentages annually. Quantifiable demand for integrated bioinformatics infrastructure, capable of processing millions of bases per sample, continues to drive investments in data systems and analytics pipelines. These numeric indicators portray Next Generation Sequencing (NGS) Market Opportunities for stakeholders seeking to capitalize on expanding sequencing volumes and supportive research investments across clinical and academic segments.

New Product Development

Recent product innovation in the Next Generation Sequencing (NGS) Market Report includes the release of next‑generation platforms capable of producing hundreds of millions of reads per run, dramatically increasing throughput for whole genome and exome analyses. Major sequencing instrument suppliers have introduced systems that reduce time‑to‑answer by measurable hours, enabling research labs to process tens of thousands of samples annually with high fidelity. Enhanced long‑read sequencing systems can now generate read lengths exceeding 100,000 base pairs, expanding capabilities in structural variation analysis and epigenomic profiling. Development of portable nanopore units, some weighing less than 1 kg, has enabled in‑field sequencing for infectious disease surveillance and environmental genomics projects. Consumable innovations include reagent kits optimized for targeted sequencing panels, RNA sequencing, and methylation assessments, each designed to handle higher sample volumes per batch, with some kits supporting up to 96 libraries per run. In bioinformatics, new software tools automate interpretation for high‑volume clinical sequencing results, handling gigabases of data per sample with reduced processing times. These numerical progressions illustrate the ongoing innovation in Next Generation Sequencing (NGS) Market Analysis, enabling broader adoption of sequencing workflows in precision medicine, pharmacogenomics, and population genomics disciplines.

Five Recent Developments

• In 2024, advanced partnerships expanded NGS microbiology solutions, including deep genotyping workflows deployed in the U.S., enhancing multi‑thousand sample capabilities in infectious disease surveillance.
• Sequencing platforms in Europe gained support via €4.8 million in regulatory funding for clinical NGS workflow integration.
• Targeted sequencing share reached approximately 57.6 % of total sequencing activity in 2024, underscoring its rapid adoption in research and diagnostics.
• Consumables usage accounted for about 48.6 % share of all NGS product deployments in 2024, highlighting repeat use in sequencing workflows.
• North America’s NGS services market registered a regional share of 45.56 % in 2024, reflecting dense service infrastructure across clinical genomics facilities.

Report Coverage of Next Generation Sequencing (NGS) Market

The Next Generation Sequencing (NGS) Market Report Coverage includes extensive analysis across sequencing technologies, product types, workflows, applications, and regional performance metrics. Quantitative segmentation in the report covers sequencing types such as Targeted Sequencing (~57.6 % share), Whole Exome Sequencing, and Whole Genome Sequencing, providing detailed numerical insights into installation counts, usage metrics, and comparative type performance. Product segmentation within the report includes consumables (~48.6 % share), platforms, and services, outlining measurable distribution of sequencer kits, reagents, and flow cells in sequencing operations. Application coverage spans academic & government research institutes, pharmaceutical and biotechnology companies, and hospitals & clinics, each quantified by sequencing volumes and operational units processed yearly. Regional outlook sections detail numeric leadership by North America (including 55.65 % share) and evolving footprints across Europe, Asia‑Pacific, and Middle East & Africa, supported by installations and lab counts. Competitive analysis includes top companies by sequence platform share and deployment numbers across major applications, offering measurable context for strategic decision‑making. The report’s scope also captures numeric figures related to bioinformatics integration, workflow performance, and service delivery metrics essential for B2B stakeholders exploring the Next Generation Sequencing (NGS) Market Insights.